GlassScriptPhysician profile
Kenneth J Hess
NPI 1275763229
$11,807.02
in general payments reported to CMS, 2019-2025
45 companies · $2,166 in 2025
The $2,166 reported for 2025 was more than what 96% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,143 · 2020: $1,169 · 2021: $1,915 · 2022: $1,116 · 2023: $2,227 · 2024: $2,071 · 2025: $2,166.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,464.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,464.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,622.68 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $1,446.42 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Abbvie INC. | $1,272.69 | 2019-2025 | |
| Lilly USA, LLC | $974.34 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Glaxosmithkline, LLC. | $755.20 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Pfizer INC. | $584.08 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $495.73 | 2019-2025 | Spravato, Xarelto |
| Novartis Pharmaceuticals Corporation | $462.50 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $431.70 | 2019-2025 | Xifaxan |
| Amgen INC. | $420.43 | 2019-2025 | Otezla, Repatha, Evenity |
| Otsuka America Pharmaceutical, INC. | $407.21 | 2022-2025 | Rexulti |
| Bayer Healthcare Pharmaceuticals INC. | $367.20 | 2021-2025 | |
| Esperion Therapeutics, INC. | $320.53 | 2020-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $310.54 | 2019-2024 | Synjardy, Jardiance |
| Merck Sharp & Dohme LLC | $205.96 | 2020-2025 | Verquvo, Belsomra, Capvaxive |
Show all 45 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $201.53 | 2020-2024 | Trintellix |
| Exact Sciences Corporation | $172.06 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Eisai INC. | $121.57 | 2020-2025 | |
| Lundbeck LLC | $107.00 | 2024-2025 | Rexulti |
| Amarin Pharma, INC. | $106.59 | 2019-2021 | |
| Dexcom, INC. | $106.15 | 2021-2025 | Dexcom G6 Transmitter |
| Sanofi-Aventis U.S. LLC | $96.81 | 2021-2023 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $70.24 | 2025 | Caplyta |
| Allergan, INC. | $66.16 | 2020 | |
| Ironwood Pharmaceuticals, INC | $60.64 | 2020-2021 | |
| Mylan Specialty L.P. | $60.50 | 2023-2024 | Yupelri |
| E.R. Squibb & Sons, L.L.C. | $59.33 | 2022-2024 | Camzyos, Eliquis |
| Axsome Therapeutics, INC. | $56.65 | 2024-2025 | Auvelity |
| Phathom Pharmaceuticals, INC. | $50.71 | 2024-2025 | Voquezna |
| Idorsia Pharmaceuticals US INC | $45.24 | 2023 | Quviviq |
| Alnylam Pharmaceuticals INC. | $41.31 | 2024 | Givlaari |
| Kowa Pharmaceuticals America, INC. | $31.62 | 2025 | Zoryve |
| Astellas Pharma US INC | $31.45 | 2023-2025 | Veozah |
| Intra-Sana Laboratories | $29.64 | 2023 | Reltone 200 Mg, Glycate, Reltone 400 Mg |
| Antares Pharma, INC. | $29.31 | 2019-2023 | Nocdurna, Tlando, Xyosted |
| Biohaven Pharmaceutical Holding Company LTD. | $27.94 | 2022 | |
| Ossur Americas, INC. | $25.70 | 2025 | |
| Inogen, INC. | $21.06 | 2022 | |
| Paratek Pharmaceuticals, INC. | $17.94 | 2023 | Nuzyra |
| Gilead Sciences, INC. | $17.38 | 2020 | |
| Alexion Pharmaceuticals, INC. | $16.41 | 2024 | Strensiq |
| Avanir Pharmaceuticals, INC. | $16.12 | 2019 | |
| Abbott Laboratories | $16.05 | 2021 | |
| Halozyme INC | $15.36 | 2023 | |
| Circassia INC. | $11.34 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kenneth Hess listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.